JP2012525422A5 - - Google Patents

Download PDF

Info

Publication number
JP2012525422A5
JP2012525422A5 JP2012508721A JP2012508721A JP2012525422A5 JP 2012525422 A5 JP2012525422 A5 JP 2012525422A5 JP 2012508721 A JP2012508721 A JP 2012508721A JP 2012508721 A JP2012508721 A JP 2012508721A JP 2012525422 A5 JP2012525422 A5 JP 2012525422A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
amount
centerkin
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012508721A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012525422A (ja
JP5498571B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/032942 external-priority patent/WO2010127096A2/en
Publication of JP2012525422A publication Critical patent/JP2012525422A/ja
Publication of JP2012525422A5 publication Critical patent/JP2012525422A5/ja
Application granted granted Critical
Publication of JP5498571B2 publication Critical patent/JP5498571B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012508721A 2009-04-30 2010-04-29 センタキンを用いた新規の治療方法 Active JP5498571B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17425709P 2009-04-30 2009-04-30
US61/174,257 2009-04-30
PCT/US2010/032942 WO2010127096A2 (en) 2009-04-30 2010-04-29 Novel therapeutic treatments using centhaquin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014044799A Division JP5727642B2 (ja) 2009-04-30 2014-03-07 センタキンを用いた新規の治療方法

Publications (3)

Publication Number Publication Date
JP2012525422A JP2012525422A (ja) 2012-10-22
JP2012525422A5 true JP2012525422A5 (enExample) 2012-11-29
JP5498571B2 JP5498571B2 (ja) 2014-05-21

Family

ID=43032771

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012508721A Active JP5498571B2 (ja) 2009-04-30 2010-04-29 センタキンを用いた新規の治療方法
JP2014044799A Active JP5727642B2 (ja) 2009-04-30 2014-03-07 センタキンを用いた新規の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014044799A Active JP5727642B2 (ja) 2009-04-30 2014-03-07 センタキンを用いた新規の治療方法

Country Status (10)

Country Link
US (2) US20120083447A1 (enExample)
EP (1) EP2424529B1 (enExample)
JP (2) JP5498571B2 (enExample)
CN (2) CN103989682B (enExample)
AU (1) AU2010241564B2 (enExample)
BR (1) BRPI1013903B1 (enExample)
CA (1) CA2759791C (enExample)
ES (1) ES2614813T3 (enExample)
PL (1) PL2424529T3 (enExample)
WO (1) WO2010127096A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5498571B2 (ja) 2009-04-30 2014-05-21 ミッドウェスタン ユニバーシティ センタキンを用いた新規の治療方法
CA2882811C (en) * 2012-08-31 2019-09-24 Pharmazz, Inc. Methods and compositions for hypotensive resuscitation
US20170326166A1 (en) * 2014-10-17 2017-11-16 University Of Virginia Patent Foundation Compositions and methods for treating pituitary tumors
ES2978951T3 (es) * 2018-05-03 2024-09-23 Univ Midwestern Composición que comprende centaquina o una sal de la misma para su uso en el tratamiento de un individuo que padece disminución aguda de la función renal
CN117440812A (zh) * 2021-05-11 2024-01-23 法尔麦兹公司 用于治疗冠状病毒病(covid-19)中的急性呼吸窘迫综合征(ards)的药物组合物及方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954987A (en) * 1972-12-22 1976-05-04 Sandoz, Inc. 2-Alkyl-4-substituted amino-quinazolines and nitrates thereof in the treatment of myocardial shock
DE2421382A1 (de) 1974-05-03 1975-11-20 Council Scient Ind Res 1-substituierte 4-(beta-2-chinolylaethyl)- piperazine und deren 1,2,3,4-tetrahydrochinolinanaloge
JPS604186B2 (ja) 1974-05-13 1985-02-01 カウンシル、オブ、サイエンテイフイツク、アンド、インダストリアルリサーチ 1―m―トリル―4―(B―2―キノリエチル)―ピペラジンの製造法
US3983121A (en) 1974-07-01 1976-09-28 Council Of Scientific And Industrial Research 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof
DE2557784C2 (de) * 1975-12-22 1986-04-17 Hoechst Ag, 6230 Frankfurt Forskolin, Verfahren zu dessen Gewinnung und diese Verbindung enthaltende pharmazeutische Präparate
US4761417A (en) * 1982-05-14 1988-08-02 Maroko Peter R Compounds, compositions and method of treatments for improving circulatory performance
CA1217141A (en) 1983-04-26 1987-01-27 Frank J. Macri Norepinephrine potentiated compositions and method of use
US5055470A (en) 1989-06-01 1991-10-08 Bristol-Myers Squibb Co. Method of treatment of ischemia in brain
US5922681A (en) 1992-09-14 1999-07-13 Warner-Lambert Company Endothelin antagonists
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6369114B1 (en) 1999-11-30 2002-04-09 Institute Of Critical Care Medicine Administration of an α2-adrenergic receptor agonist to enhance cardiopulmonary resuscitation
GB0013378D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
SE0004455D0 (sv) 2000-12-01 2000-12-01 Milos Pekny Method for neuron regeneration in the central nervous system
US6573285B2 (en) 2000-12-21 2003-06-03 Bristol-Myers Squibb Co. Method for preventing or treating pain by administering an endothelin antagonist
US20030232787A1 (en) 2001-05-08 2003-12-18 Dooley David James Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
US20030104976A1 (en) 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
US7030082B2 (en) 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7973064B2 (en) * 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US7351692B2 (en) * 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
JP2006508086A (ja) 2002-10-24 2006-03-09 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 固形腫瘍を予防および治療するための方法および組成物
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
AU2003280117B2 (en) 2002-11-20 2009-09-10 Newron Sweden Ab Compounds and methods for increasing neurogenesis
EP1768647B1 (en) 2004-06-17 2012-08-08 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agent
WO2008043102A2 (en) 2006-10-06 2008-04-10 Transition Therapeutics Inc. Vasoactive intestinal polypeptide compositions
WO2007027582A2 (en) 2005-08-31 2007-03-08 University Of Tennessee Research Foundation Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
US9829494B2 (en) 2005-12-01 2017-11-28 Adrenomed Ag Methods of treatment using ADM antibodies
EA200870365A1 (ru) 2006-03-23 2009-02-27 Амилин Фармасьютикалз, Инк. Эндотелин и агонисты рецепторов к эндотелину в лечении заболеваний обмена веществ
US8623823B2 (en) 2007-08-21 2014-01-07 Midwestern University Methods for treatment of stroke or cerebrovascular accidents using an ETB receptor agonist
US20100189802A1 (en) 2007-08-21 2010-07-29 Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation Method for treatment of vascular hyperpermeability
CN101374259B (zh) 2007-08-22 2012-08-08 华为技术有限公司 实现多媒体彩铃和多媒体彩像业务的方法和装置
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
JP5498571B2 (ja) 2009-04-30 2014-05-21 ミッドウェスタン ユニバーシティ センタキンを用いた新規の治療方法
BRPI1013904A2 (pt) 2009-04-30 2016-07-19 Univ Midwestern método e composição para tratar cetoacidose diabética
EP2582692B1 (en) 2010-06-17 2015-07-22 Janssen Pharmaceutica NV Cyclohexyl-azetidinyl antagonists of ccr2
KR101418941B1 (ko) 2011-04-04 2014-07-15 서울대학교병원 엔도텔린을 유효성분으로 함유하는 허혈성질환 치료용 조성물
CA2882811C (en) 2012-08-31 2019-09-24 Pharmazz, Inc. Methods and compositions for hypotensive resuscitation
CN113384701A (zh) 2013-07-08 2021-09-14 美国中西部大学 使用内皮素-b受体激动剂治疗神经精神病症的组合物和方法
ES2978951T3 (es) 2018-05-03 2024-09-23 Univ Midwestern Composición que comprende centaquina o una sal de la misma para su uso en el tratamiento de un individuo que padece disminución aguda de la función renal

Similar Documents

Publication Publication Date Title
JP2013525444A5 (enExample)
JP2013032389A5 (enExample)
JP2016510326A5 (enExample)
JP2015501783A5 (enExample)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2010522242A5 (enExample)
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
JP2013518107A5 (enExample)
JP2012255026A5 (enExample)
JP2013542247A5 (enExample)
JP2012144574A5 (enExample)
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
JP2012092110A5 (enExample)
JP2011518833A5 (enExample)
JP2013520405A5 (enExample)
JP2014507477A5 (enExample)
JP2013507408A5 (enExample)
JP2015516419A5 (enExample)
MX2012000488A (es) Terapia de combinacion para el tratamiento de la diabetes.
JP2013166781A5 (enExample)
ME02405B (me) Spojevi pirazola као inhibitori sglt1
JP2012525422A5 (enExample)
JP2014148552A5 (enExample)
EA201171229A1 (ru) Терапевтическое применение производных хиназолиндиона при сердечно-сосудистых заболеваниях
FR2961695B1 (fr) Utilisation de composes dans le traitement ou la prevention de troubles cutanes